GET THE APP

MicroRNA-122 Therapeutic for ischemic stroke
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

MicroRNA-122 Therapeutic for ischemic stroke


Joint Event on 2nd International Conference on Cancer Biology, Therapeutics and Drug Discovery and Delivery & 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics

October 03-04, 2018 | Los Angeles, USA

Da Zhi Liu

University of California at Davis, USA

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Based upon our previous findings that microRNA-122 (miR-122) were decreased in peripheral blood of both humans and rats after ischemic stroke, we hypothesized that elevating miR-122 in blood might improve outcomes after ischemic stroke. Using the in vivo polyethylene glycol 2000 (PEG)-liposome based miRNA transfection system and the rat middle cerebral artery occlusion (MCAO) model, we recently demonstrated that intravenous (i.v.) miR-122 mimic, given immediately after MCAO, elevated miR- 122 in peripheral blood, prevented neurological impairments, and reduced brain infarction volume by 90% after MCAO in rats. Moreover, the results showed that miR-122 mimic, given 6 hr after MCAO, attenuates neurological impairments and reduced brain infarction volume by 54% after MCAO in rats. Using Taqman PCR based assays, we demonstrate fourteen direct miR-122 target genes (e.g. Pla2g2a, Nos2, Vcam1, Clic4, Ucp2, Dlg2, and others) decrease in blood leukocytes following miR-122 mimic treatment after MCAO in rats. Focusing on ONE miR-122 target gene (Pla2g2a), we demonstrate that miR-122 mimic decreases Pla2g2a expression in brain microvascular endothelial cells (BMVECs) after MCAO in rats. Luciferase reporter assays confirmed that miR-122 bound to wild-type but not mutated 3â??UTR of Pla2g2a. These results show that Pla2g2a is decreased in leukocytes and BMVECs following miR-122 mimic treatment after MCAO, which likely contributes to the therapeutic effects of miR-122 mimic on ischemic stroke. Acknowledgments: This study was supported by the UC Davis Innovative Development Award and NIH grants R01NS089901 (DZL) and RO1NS101718 (FRS). There were no conflicts of interest.

Biography :

E-mail: dzliu@ucdavis.edu

 

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward